Persist AI Raises $12M in Series A to Slash Drug Formulation Discovery Time by Up to 50% with AI and Automation

Persist AI, a trailblazer in the pharmaceutical technology space, is excited to announce a remarkable funding milestone, having raised $12 million to accelerate its groundbreaking mission. In an industry where developing extended-release PLG drug formulations typically requires investments exceeding $10 million and spans 5-10 years, Persist AI is redefining the landscape. By leveraging advanced automation and machine learning technologies, the company has developed a platform that dramatically shortens the formulation discovery process by 30-50%, offering drug manufacturers and contract research organizations a faster, more efficient path to innovation. The fresh infusion of capital will be strategically deployed to enhance Persist AI’s proprietary platform, expand its research and development efforts, and scale operations to meet the growing demand within the pharmaceutical community. This funding round not only underscores market confidence in Persist AI’s vision but also reinforces its commitment to addressing long-standing challenges associated with drug formulation and delivery. With the pharmaceutical industry under constant pressure to innovate and deliver life-changing therapies, Persist AI’s technology stands as a beacon of transformation, streamlining processes that traditionally have been time-intensive and resource-demanding. This investment is a testament to the company’s ability to merge cutting-edge technology with critical market needs, promising significant reductions in development timelines and costs for its clients. As Persist AI continues to break new ground, stakeholders can look forward to a future where pharmaceutical advancements are not only more rapid but also more precise, ultimately benefiting patients worldwide by getting improved therapeutic solutions to market faster.